Reflections on the Opportunities and Challenges of applying Experience-Based Co-Design (EBCD) to Phase 1 Clinical Trials in Oncology

Nils Graber*, Nina Canova, Denise Bryant-Lukosius, Glenn Robert, Blanca Navarro-Rodrigo, Lionel Trueb, George Coukos, Manuela Eicher, Tourane Corbiere, Sara Colomer-Lahiguera

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

39 Downloads (Pure)

Abstract

Experience-Based Co-Design (EBCD) is a multi-stage participatory action research process which was developed originally to increase patient involvement in service improvement initiatives. We reflect on the opportunities and challenges of applying EBCD in a new context of early-phase clinical trials in oncology where experimental treatments are increasingly perceived as a therapeutic option and, in certain instances, their efficacy may lead to accelerated approval facilitating a swifter integration into standard care. We propose that the opportunity of applying EBCD in such trials lies in improving the delivery of patient-centered care, care coordination, and support during the transition from experimental to standard care. Three potential challenges when applying EBCD in early-phase clinical trials are discussed related to: the need for standardization in trial processes; planning EBCD in a context of high uncertainty; and vulnerability of patient populations. We reflect on potential solutions and argue that adopting co-design as an approach within early-phase clinical trials could enable improvements in the process of care simultaneously to the development of novel therapies.
Original languageEnglish
Number of pages14
JournalHealth expectations : an international journal of public participation in health care and health policy
Publication statusAccepted/In press - 25 Apr 2024

Keywords

  • Co-design
  • Experience-based Co-design
  • Clinical trials
  • Oncology

Fingerprint

Dive into the research topics of 'Reflections on the Opportunities and Challenges of applying Experience-Based Co-Design (EBCD) to Phase 1 Clinical Trials in Oncology'. Together they form a unique fingerprint.

Cite this